ALAlexander Loch

Alexander Loch

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alexander Loch has a total of 89 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Drug‐Coated Balloon Intervention in Large Coronary Arteries: Immediate Procedural Results and One‐Year Follow‐Up

    by Alexander Loch, Vineesh Chandra Segaran, David Kwong Yi Vern, Victoria Wen Yeng Teoh, Mahmoud Danaee

    Background: Drug‐coated balloons (DCBs) are an established treatment for in‐stent restenosis and small‐vessel coronary disease, but evidence for large de novo coronary artery lesions remains limited. Methods: We prospectively evaluated patients undergoing percutaneous coronary intervention (PCI) with DCB for de novo lesions in large coronary arteries (reference vessel diameter ≥ 2.75 mm). All lesions underwent adequate predilatation, and DCBs were used as the definitive treatment strategy. Bailout stenting was performed in cases of significant recoil or flow‐limiting dissection. Outcomes included procedural success, in‐hospital complications, and major adverse cardiovascular events (MACEs) at 12‐month follow‐up, defined as cardiac death, target vessel myocardial infarction, or clinically driven target lesion revascularization (TLR). Results: A total of 539 DCB‐treated lesions were evaluated, of which 451 were excluded. The final cohort comprised 88 de novo lesions in large coronary vessels from 75 patients. DCB‐only treatment was performed in 65.9%; 34.1% underwent additional PCI with stenting of nonindex lesions. Post‐DCB dissections occurred in 50% and were predominantly NHLBI type A. Stenting was required in three cases, including one acute vessel closure, one severe recoil with residual stenosis during the index procedure, and one early vessel closure 11 h after the index procedure requiring repeat PCI. Mean acute gain on QCA was 0.93 ± 0.45 mm. Complete 12‐month follow‐up was achieved in 100% of patients. MACE at 12‐month follow‐up occurred in 2.7% (2/75), comprising one non‐ST‐segment elevation myocardial infarction and one clinically driven TLR. TLR was 1.3% at 12 months. One noncardiac death occurred and was not included in the MACE endpoint. No stroke or major bleeding was observed. Conclusions: DCB angioplasty in selected de novo large coronary lesions was feasible and associated with high procedural success and favorable 1‐year outcomes. Larger studies with longer follow‐ups are warranted to confirm these findings.

  • Open Access

    The Use of Quantitative Flow Ratio for Decisions and Outcomes in Percutaneous Coronary Intervention Study

    by Samshol Sukahri, Ahmad Syadi Mahmood Zuhdi, Kok Han Chee, Imran Zainal Abidin, Ramesh Singh Argan Singh, Alexander Loch, Nor Ashikin Md Sari, Nursyuhada Khairul Anuar, Kee Wei Lee, Muhammad Azlan Aseri, et al.

    Background: This pilot study explores the impact of quantitative flow ratio (QFR) guidance on decision-making for angioplasty and post-intervention procedures in stable coronary artery disease. Aim: The primary aim was to evaluate the vessel-oriented composite endpoint (VOCE) at 6 months, encompassing cardiac death, vessel-related MI and ischaemia-driven target vessel revascularisation. Secondary objectives included assessing individual components of VOCE and the influence that the QFR had on decision-making before and after interventions. Methods: The pilot study was conducted from 1 January to 31 July 2023 and included all angiogram patients. Cardiologists used QFR readings for decision-making, with QFR >0.80 indicating non-significance and 0.90 indicated that no further intervention was necessary. Results: A total of 770 subjects were screened. Most of the patients in the post-percutaneous coronary intervention (PCI) without QFR group were Malaysian (36.1%), while there were more Chinese patients in the PCI with QFR group (49.2%). Hypertension was the primary risk factor for both groups (79.5% and 73%, respectively). Decision changes were more common in pre-intervention assessments (39%), with 34% of these opted not to proceed whereas 66% agreed to proceed. Post-PCI decision changes were less common (22%); 19% of these opted for further intervention and 81% accepted the angiographic results before the QFR reading. VOCE at 6-month follow-up showed one cardiac death in the PCI without QFR group and none in the PCI with QFR group (p=0.316). Conclusion: QFR readings demonstrated significant value in guiding pre-PCI decisions. This study underscores the potential for enhanced decision-making and improved patient outcomes by using QFR-guided interventions.


  • Open Access

    A Transesophageal Cardiovascular Intervention

    by Alexander Loch, Victoria Wen Yeng Teoh, Ida Normiha Hilmi

    Endoscopic ultrasonography-guided transesophageal pericardiocentesis was performed for a posteriorly located effusion not amenable to transthoracic drainage in a 58-year-old woman with a history of recurrent breast adenocarcinoma who presented with dyspnea. The patient had a pericardial effusion that resulted in cardiac tamponade. Transthoracic pericardiocentesis was unsuitable because of the posterior location of the effusion. Pericardiocentesis via the transesophageal route was performed. The pericardial sac was punctured with a 19-gauge needle, and 245 mL of pericardial fluid were aspirated, resulting in the resolution of the tamponade physiology. Endoscopic ultrasonography-guided transesophageal drainage is a novel and promising therapeutic option for posteriorly located pericardial effusions.


  • Aortic root pseudoaneurysm: a case report and literature review

    by Pravinthiran Manokaran, Sivakumar Krishnasamy, Raja Rizal Azman bin Raja Aman, Victoria Wen Yeng Teoh, Alexander Loch

    Pseudoaneurysms of the aortic root are rare. A case of prosthetic aortic valve infection progressing from a confined intramural abscess to a ruptured abscess communicating with the aorta and forming a large pseudoaneurysm is described. Additionally, data from all cases and case series, published between 2000 and 2021, was analyzed. A PUBMED search for the keywords “aortic root mycotic aneurysm,” “aortic root abscess AND infective endocarditis,” and “aortic root mycotic aneurysm AND infective endocarditis” yielded 152 publications (with 157 cases described): Aortic pseudoaneurysm is more common in males (80.9%, n = 127). Mean age is 51 years (4 months–84 years). The most common symptom is fever (68.5%, n = 102). Mean time until diagnosis is 27.2 days. Embolic complications are present in 17.8% (n = 28) at diagnosis. Most cases are due to valvular infections (n = 72 cases, 45.9%). Prior cardiac surgery is documented in 49.0% (n = 77). The mean time interval for developing aortic root abscess following heart surgery is 32.2 months. 22.3% (n = 35) are immunocompromised. Aetiological agents were Staphylococcus sp. (34.1%, n = 47) and Streptococcus sp. (23.2%, n = 32). Mean antimicrobial therapy lasts 58.5 days. Outcome with surgery is superior to medical treatment: overall inpatient mortality 18.5% (n = 27); with surgery 12.2% (n = 15 out of 123 patients), with only medical management 47.8% (n = 11 out of 23 patients). In conclusion, aortic root pseudoaneurysm occurs most commonly in middle-aged male patients. History of prior aortic procedures is commonly present. Correct diagnosis hinges on detailed history, transoesophageal echocardiography, and computed tomography (CT) aorta. Surgery is the preferred therapeutic option.


  • Recurrent pericardial effusion: a treatable cause not to be overlooked

    by Victoria Wen Yeng Teoh, Iffa Liana Kamarulata, Alexander Loch


  • Open Access

    A simple pleural effusion or not?

    by Victoria Wen Yeng Teoh, Mohd Adli Deraman, Alexander Loch

    A 60-year-old man presented with a 2-week history of progressive dyspnea and bilateral leg edema. He had undergone a prosthetic mitral valve replacement 9 years earlier. The patient was in respiratory distress (respiratory rate 32/min, oxygen saturation 86% on air, heart rate 124/min, blood pressure 109/56 mmHg). Examination revealed bilateral lung crackles and reduced air entry with dullness to percussion and elevated jugular venous pressure. The electrocardiogram showed sinus tachycardia. A chest X-ray (CXR) (Figure 1) and bedside lung ultrasonography were performed (Figure 2A). A diagnosis of a large pleural effusion was made and urgent thoracocentesis was considered in view of the patient’s respiratory distress. A repeat ultrasonographic scan with adjusted angulation to identify the most suitable entry point for the chest drain (Figure 2B) yielded new results that led to the cancellation of the thoracocentesis.

  • Open Access

    Leucine-Rich Alpha-2-Glycoprotein: A Novel Predictor of Diastolic Dysfunction

    by Alexander Loch, Kok Leng Tan, Mahmoud Danaee, Iskandar Idris, Mei Li Ng

    Leucine-rich α2-glycoprotein (LRG1) mediates cardiac fibrocyte activation. It is upregulated in inflammatory conditions, atherosclerosis, and fibrosis. Diastolic dysfunction (DD) is due to myocardial fibrosis. This cross-sectional study examined the relationship between LRG1 and DD. Patients with symptoms of chronic coronary ischemia were recruited. Patients with symptoms of overt heart failure, ejection fraction (EF) < 55%, impaired renal function, infection, and recent trauma were excluded from the study. Clinical parameters examined were SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) score, echocardiographic assessment, and LRG1 levels. Binary stepwise logistic regression was used to evaluate the association between LRG1 and DD. Receiver Operating Characteristic (ROC) analysis was used to determine optimal cut-off values and predictive performance of LRG1. A total of 94 patients were enrolled in the study, with 47 having a clinical diagnosis of DD. Plasma LRG1 was significantly (U = 417.00, p < 0.001) higher in the DD group (M = 14) compared to the No-DD group (M = 8) by Mann–Whitney U test. There were higher SYNTAX scores in the DD group (M = 24.5) compared with No-DD (M = 7). LRG1 had significant predictability of DD (OR = 1.32 (95% CI: 1.14–1.53)). The ROC showed an AUC = 0.89 (95% CI: 0.82–0.95). LRG1 had a 78% sensitivity (95% CI: 65.3–87.7) and 72.3% specificity (95% CI: 57.4–84.4) for predicting DD at a cut-off value of “9”. In conclusion, we identified LRG1 as a novel independent predictor of DD. Further studies are warranted to validate the utility of LRG1 in predicting DD.


  • Open Access

    ARNI Versus Perindopril for Remodeling in HFrEF. A Cohort Study

    by Noor Muhammad Azlan Shah Bin Atan, Mohd Firdaus Bin Hadi, Victoria Wen Yeng Teoh, Mahmoud Danaee, Alexander Loch

    Introduction: Ventricular remodeling is a mal-adaptive process. Both angiotensin-converting enzyme inhibitors and sacubitril/valsartan have been shown to reverse remodeling in mostly uncontrolled observational studies. There is a lack of head-to-head studies. Methods: This cohort study compares the remodeling effects of angiotensin receptor blockers combined with a neprilysin inhibitor (ARNI) and perindopril in heart failure with reduced ejection fraction (HFrEF) patients between January 2017 and December 2020. Inclusion criteria: (i) age > 18 years, (ii) recent diagnosis of de-novo HFrEF (EF < 40%), (iii) baseline echocardiography performed not more than 2 months prior to treatment onset, and (iv) follow-up echocardiography performed not earlier than 6 months and not later than 18 months posttreatment onset. No prior treatment with renin–angiotensin–aldosterone system inhibitors was permitted in the ARNI group. Left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume (LVEDV), and left ventricular end-systolic volume (LVESV) were analyzed. A two-way repeated measure ANOVA (for normally distributed) and generalized estimating equation test for nonnormally distributed interval dependent variables. Mean comparison between and within groups was performed using the Bonferroni test. Results: Following an average treatment period of 9 months, LVEF improved from 24.9% to 36.4% for ARNI and from 28.7% to 40.5% for perindopril, increments of 11.5% and 11.8% resp. (Bonferroni test [ P ≤ .05]). LVEDV was reduced by 8.4 mL and 3.2 mL, and LVESV by 17.9 mL and 10.8 mL for ARNI and perindopril resp. Only the reduction of LVESV for ARNI was statistically significant ( P = .007). Conclusion: Both ARNI and perindopril yielded a significant improvement in the LVEF within 9 months. The remodeling effect of ARNI seems stronger because of the greater improvements in left ventricular volumes.


  • Open Access

    Genetic investigation of point mutations in sarcomeric genes in Malaysian patients with cardiomyopathy

    by E-Wei Tan, Kek Heng Chua, Sherry Usun Jones, Lay Koon Tan, Alexander Loch, Boon Pin Kee

  • Open Access

    Whole mitochondrial genome sequencing of Malaysian patients with cardiomyopathy

    by Sheh Wen Kuan, Kek Heng Chua, E-Wei Tan, Lay Koon Tan, Alexander Loch, Boon Pin Kee

    Cardiomyopathy (CMP) constitutes a diverse group of myocardium diseases affecting the pumping ability of the heart. Genetic predisposition is among the major factors affecting the development of CMP. Globally, there are over 100 genes in autosomal and mitochondrial DNA (mtDNA) that have been reported to be associated with the pathogenesis of CMP. However, most of the genetic studies have been conducted in Western countries, with limited data being available for the Asian population. Therefore, this study aims to investigate the mutation spectrum in the mitochondrial genome of 145 CMP patients in Malaysia. Long-range PCR was employed to amplify the entire mtDNA, and whole mitochondrial genome sequencing was conducted on the MiSeq platform. Raw data was quality checked, mapped, and aligned to the revised Cambridge Reference Sequence (rCRS). Variants were named, annotated, and filtered. The sequencing revealed 1,077 variants, including 18 novel and 17 CMP and/or mitochondrial disease-associated variants after filtering. In-silico predictions suggested that three of the novel variants (m.8573G>C, m.11916T>A and m.11918T>G) in this study are potentially pathogenic. Two confirmed pathogenic variants (m.1555A>G and m.11778G>A) were also found in the CMP patients. The findings of this study shed light on the distribution of mitochondrial mutations in Malaysian CMP patients. Further functional studies are required to elucidate the role of these variants in the development of CMP.